Production, Quality Control and Biological Evaluation of 166Ho-PDTMP as a Possible Bone Palliation Agent

Authors

  • Ali Bahrami-Samani Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
  • Amir Reza Jalilian Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran 2 Faculty
  • Hassan Yousefnia Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
  • Hossein Afarideh Faculty of Energy Engineering and Physics, Amirkabir University of Technology, Tehran, Iran
  • Mohammad Ghannadi-Maragheh Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
  • Samaneh Zolghadri Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran 2 Faculty of Energy Engineering and Physics, Amirkabir University of Technology, Tehran, Iran
  • Zohreh Naseri Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Abstract:

Objective(s):In this study, 166Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) (166Ho-PDTMP) complex  was prepared as a bone palliation agent. Materials and Methods:The complex was successfully prepared using an in-house synthesized EDTMP ligand and 166HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural Ho(NO3)3 samples  followed by radiolabeling and stability studies. Biodistribution in wild type rats was also peformed. Results: The complex was prepared with thespecific activity of 278 GBq/mg and high radiochemical purity (>99%, checked by ITLC). 166Ho-PDTMP complex was stabilized in the final preparation and in the presence of human serum (>90%) up to 72 hr. The biodistribution of 166Ho-PDTMP in wild-type rats demonstrated significant bone uptake was up to 48 hr compared to 166HoCl3. Conclusion: The produced 166Ho-PDTMP properties suggest a possible new bone palliative therapeutic to overcome the metastatic bone pains.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

production, quality control and biological evaluation of 166ho-pdtmp as a possible bone palliation agent

objective(s):in this study, 166ho-1,2-propylene di-amino tetra(methy1enephosphonicacid) (166ho-pdtmp) complex  was prepared as a bone palliation agent. materials and methods:the complex was successfully prepared using an in-house synthesized edtmp ligand and 166hocl3. ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural ho(no3)3 samples  followed by radio...

full text

Production, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: 153Sm-TTHMP was prepared starting from 153<...

full text

production, quality control and biological evaluation of 153sm-tthmp as a possible bone palliation agent

introduction: various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153sm-edtmp. in this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. methods: 153sm-tthmp was prepared starting from 153sm-smcl3, prepared by neutro...

full text

Production, quality control and biological evaluation of Sm-TTHMP as a possible bone palliation agent

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: Sm-TTHMP was prepared starting from Sm-SmCl3, prepared by neutron activati...

full text

Production, quality control, and biodistribution studies of 141Ce-EDTMP as a potential bone pain palliation agent

The purpose of the present work was to introduce 141Ce-EDTMP as a novel potential future pain palliative agent to patients suffering from disseminated skeletal metastases and diagnostic imaging radioisotope as well. Cerium-141 [T1/2 = 32.501 days, Eβ (max) = 0.580 (29.8%) and 0.435(70.2%) MeV, Eγ = 145.44 (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 16  issue 5

pages  719- 725

publication date 2013-05-01

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023